PE20011104A1 - Un proceso para la preparacion de analogos de epotilona - Google Patents
Un proceso para la preparacion de analogos de epotilonaInfo
- Publication number
- PE20011104A1 PE20011104A1 PE2001000256A PE2001000256A PE20011104A1 PE 20011104 A1 PE20011104 A1 PE 20011104A1 PE 2001000256 A PE2001000256 A PE 2001000256A PE 2001000256 A PE2001000256 A PE 2001000256A PE 20011104 A1 PE20011104 A1 PE 20011104A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- aryl
- epotilone
- analogs
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- -1 2-METHYL-4-THIAZOLYL Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102220517591 Methyl-CpG-binding domain protein 3-like 2B_R11C_mutation Human genes 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000007822 coupling agent Substances 0.000 abstract 1
- ORGHESHFQPYLAO-UHFFFAOYSA-N vinyl radical Chemical compound C=[CH] ORGHESHFQPYLAO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A ANALOGOS DE EPOTILONA FORMULA I DONDE Q ES EL GRUPO a, b; M ES O, S, NR6, CR9R10; Z ES R16-N(R17)(R18), R16-P(R17)(R18), R16-Ar(R17)(R18); R1-R5 Y R11-R15 SON H, ALQUILO, ARILO, HETEROCICLO, DONDE R1 Y R2 SON ALQUILO Y JUNTOS FORMAN UN CICLOALQUILO; R6 ES H, ALQUILO, ARILO, CICLOALQUILO, ENTRE OTROS; R8 ES H, ALQUILO, R11C=O, R12OC=O, R13SO2; R9 Y R10 SON H, HALO, ALQUILO, ARILO, HETEROCICLO ENTRE OTROS; R16, R17 Y R18 SON ALQUILO, ARILO, ARALQUILO. SE REFIERE TAMBIEN A UN PROCESO PARA LA PREPARACION DE ANALOGOS DE EPOTILONA TAL COMO [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-DIHIDROXI -8,8,10,12,16-PENTAMETIL-3-[1-METIL-2-(2-METIL-4-TIAZOLIL)ETENIL]-4-AZA-17-OXABICICLO [14.1.0]HEPTADECAN-5,9-DIONA Y COMPUESTOS INTERMEDIOS MEDIANTE LA FORMACION DE NUEVAS EPOTILONAS DE ANILLO ABIERTO Y LLEVAR A CABO UNA REACCION DE MACROLACTAMIZACION CON UN AGENTE DE ACOPLAMIENTO TAL COMO 1-(3-DIMETILAMINOPROPIL)-3-ETILCARBODIIMIDA, ENTRE OTROS. LOS COMPUESTOS DE FORMULA I SON UTILES PARA EL TRATAMIENTO DE CANCER, TUMORES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52852600A | 2000-03-20 | 2000-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20011104A1 true PE20011104A1 (es) | 2001-12-02 |
Family
ID=24106039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001000256A PE20011104A1 (es) | 2000-03-20 | 2001-03-20 | Un proceso para la preparacion de analogos de epotilona |
Country Status (16)
Country | Link |
---|---|
US (2) | US6518421B1 (es) |
EP (2) | EP1265878B1 (es) |
JP (1) | JP4966468B2 (es) |
KR (1) | KR100758069B1 (es) |
AT (1) | ATE516280T1 (es) |
AU (2) | AU4560801A (es) |
CA (1) | CA2404212C (es) |
ES (1) | ES2367703T3 (es) |
HK (1) | HK1050680A1 (es) |
HU (1) | HU229348B1 (es) |
IL (2) | IL151474A0 (es) |
MX (1) | MXPA02009165A (es) |
PE (1) | PE20011104A1 (es) |
TW (1) | TWI310383B (es) |
UY (1) | UY26624A1 (es) |
WO (1) | WO2001070716A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0977563B1 (en) | 1996-12-03 | 2005-10-12 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6867305B2 (en) * | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6780620B1 (en) * | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
WO2002030356A2 (en) | 2000-10-13 | 2002-04-18 | The University Of Mississipi | Synthesis of epothilones and relates analogs |
HUP0302567A2 (hu) | 2001-01-25 | 2003-12-29 | Bristol-Myers Squibb Co. | Epotilon analógokat tartalmazó parenterális adagolási formák és eljárás az előállításukra |
WO2002066038A1 (en) | 2001-02-20 | 2002-08-29 | Bristol-Myers Squibb Company | Treatment of refractory tumors using epothilone derivatives |
NZ527557A (en) | 2001-02-27 | 2005-05-27 | Biotechnolog Forschung Gmbh | Degradation of epothilones and ethynyl substituted epothilones |
TW200403994A (en) * | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
CN1759115A (zh) * | 2002-08-23 | 2006-04-12 | 索隆-基特林癌症研究协会 | 埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途 |
US7649006B2 (en) * | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
DE10331004A1 (de) * | 2003-07-03 | 2005-02-24 | Schering Ag | Verfahren für die Herstellung von C1-C15-Fragmenten von Epothilonen und deren Derivaten |
US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
EP1559447A1 (en) * | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
US20090004277A1 (en) * | 2004-05-18 | 2009-01-01 | Franchini Miriam K | Nanoparticle dispersion containing lactam compound |
EP1824458A1 (en) * | 2004-11-18 | 2007-08-29 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof |
PE20061058A1 (es) | 2004-11-18 | 2006-10-13 | Bristol Myers Squibb Co | Composicion farmaceutica que comprende ixabepilona y proceso de preparacion |
EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
JP2008536479A (ja) | 2005-02-11 | 2008-09-11 | ユニバーシティ オブ サザン カリフォルニア | ジスルフィド架橋を有するタンパク質の発現法 |
US8008256B2 (en) * | 2006-05-01 | 2011-08-30 | University Of Southern California | Combination therapy for treatment of cancer |
US8463852B2 (en) * | 2006-10-06 | 2013-06-11 | Oracle International Corporation | Groupware portlets for integrating a portal with groupware systems |
EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
DE102007059752A1 (de) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone |
EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
WO2011153221A1 (en) | 2010-06-01 | 2011-12-08 | Plus Chemicals Sa | Solid state forms of ixabepilone |
WO2013008091A1 (en) * | 2011-07-13 | 2013-01-17 | Xellia Pharmaceuticals Aps | Manufacturing of epothilone derivatives and the use thereof |
US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2013164102A1 (en) | 2012-04-30 | 2013-11-07 | Xellia Pharmaceuticals Aps | Process for preparation of ixabepilone and intermediates useful in said process. |
WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
WO2014072482A1 (en) | 2012-11-09 | 2014-05-15 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
US9309259B2 (en) | 2013-03-08 | 2016-04-12 | Scinopharm Taiwan, Ltd. | Process for ixabepilone, and intermediates thereof |
US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
KR20160042871A (ko) | 2013-06-21 | 2016-04-20 | 이나뜨 파르마, 에스.아. | 폴리펩티드의 효소적 콘쥬게이션 |
WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
WO2021204188A1 (zh) * | 2020-04-08 | 2021-10-14 | 北京华昊中天生物医药股份有限公司 | 优替德隆半水合物单晶及其制备方法与应用 |
CN112409366A (zh) * | 2020-11-30 | 2021-02-26 | 湖北宏中药业股份有限公司 | 一种伊沙匹隆二聚体的高收率制备方法 |
CN112375085A (zh) * | 2020-11-30 | 2021-02-19 | 湖北宏中药业股份有限公司 | 一种伊沙匹隆反应液的高收率高纯度处理方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
DE19542986A1 (de) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
DE59609305D1 (de) | 1995-11-17 | 2002-07-11 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Herstellung |
DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
DE19636343C1 (de) | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
PT941227E (pt) | 1996-11-18 | 2004-08-31 | Biotechnolog Forschung Mbh Gbf | Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP0977563B1 (en) | 1996-12-03 | 2005-10-12 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
DE19707053B4 (de) | 1997-02-21 | 2008-03-27 | Sipra Patententwicklungs- Und Beteiligungsgesellschaft Mbh | Hoch/Tief-Plüschstrickware sowie Verfahren und Vorrichtung zu ihrer Herstellung |
EP1201666A3 (de) | 1997-02-25 | 2003-03-05 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Seitenkettenmodifizierte Epothilone |
DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
JP4065573B2 (ja) | 1997-04-18 | 2008-03-26 | ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス |
DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
AU8542898A (en) | 1997-07-16 | 1999-02-10 | Schering Aktiengesellschaft | Thiazole derivatives, method for their production and use |
DK1005465T3 (da) | 1997-08-09 | 2007-11-05 | Bayer Schering Pharma Ag | Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
JP4644364B2 (ja) | 1998-02-05 | 2011-03-02 | ノバルティス アーゲー | エポシロン組成物 |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
JP2002504540A (ja) | 1998-02-25 | 2002-02-12 | スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ | エポチロンの合成、その中間体およびそのアナログ |
DE19820599A1 (de) | 1998-05-08 | 1999-11-11 | Biotechnolog Forschung Gmbh | Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung |
AU5036999A (en) | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
AU768220B2 (en) | 1998-11-20 | 2003-12-04 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
AU2795000A (en) | 1998-12-22 | 2000-07-12 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
EA009206B1 (ru) | 1999-02-18 | 2007-12-28 | Шеринг Акциенгезельшафт | Производные 16-галогенэпотилона и их фармацевтическое использование |
US6211412B1 (en) | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
PE20010116A1 (es) | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
KR101406635B1 (ko) | 2002-09-23 | 2014-06-11 | 브리스톨-마이어스 스큅 컴퍼니 | 에포틸론 b의 제조, 분리 및 정제 방법, 및 에포틸론 b의 x-선 결정 구조 |
-
2001
- 2001-02-01 US US09/775,361 patent/US6518421B1/en not_active Ceased
- 2001-03-12 MX MXPA02009165A patent/MXPA02009165A/es active IP Right Grant
- 2001-03-12 CA CA2404212A patent/CA2404212C/en not_active Expired - Fee Related
- 2001-03-12 AU AU4560801A patent/AU4560801A/xx active Pending
- 2001-03-12 EP EP01918544A patent/EP1265878B1/en not_active Expired - Lifetime
- 2001-03-12 AT AT01918544T patent/ATE516280T1/de not_active IP Right Cessation
- 2001-03-12 IL IL15147401A patent/IL151474A0/xx unknown
- 2001-03-12 JP JP2001568920A patent/JP4966468B2/ja not_active Expired - Fee Related
- 2001-03-12 ES ES01918544T patent/ES2367703T3/es not_active Expired - Lifetime
- 2001-03-12 WO PCT/US2001/007749 patent/WO2001070716A1/en active Application Filing
- 2001-03-12 HU HU0300693A patent/HU229348B1/hu not_active IP Right Cessation
- 2001-03-12 AU AU2001245608A patent/AU2001245608B2/en not_active Ceased
- 2001-03-12 EP EP07020071A patent/EP1882690A3/en not_active Withdrawn
- 2001-03-12 KR KR1020027012290A patent/KR100758069B1/ko not_active IP Right Cessation
- 2001-03-14 TW TW090105973A patent/TWI310383B/zh not_active IP Right Cessation
- 2001-03-19 UY UY26624A patent/UY26624A1/es not_active Application Discontinuation
- 2001-03-20 PE PE2001000256A patent/PE20011104A1/es not_active Application Discontinuation
-
2002
- 2002-08-26 IL IL151474A patent/IL151474A/en not_active IP Right Cessation
-
2003
- 2003-04-14 HK HK03102703.1A patent/HK1050680A1/xx not_active IP Right Cessation
-
2005
- 2005-02-11 US US11/056,606 patent/USRE39356E1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2003528090A (ja) | 2003-09-24 |
ES2367703T3 (es) | 2011-11-07 |
HUP0300693A2 (hu) | 2003-08-28 |
CA2404212C (en) | 2012-05-01 |
HUP0300693A3 (en) | 2005-11-28 |
JP4966468B2 (ja) | 2012-07-04 |
KR100758069B1 (ko) | 2007-09-11 |
KR20020081463A (ko) | 2002-10-26 |
HK1050680A1 (en) | 2003-07-04 |
AU2001245608B2 (en) | 2006-09-14 |
ATE516280T1 (de) | 2011-07-15 |
CA2404212A1 (en) | 2001-09-27 |
US6518421B1 (en) | 2003-02-11 |
USRE39356E1 (en) | 2006-10-17 |
MXPA02009165A (es) | 2004-08-12 |
UY26624A1 (es) | 2001-10-25 |
HU229348B1 (en) | 2013-11-28 |
WO2001070716A1 (en) | 2001-09-27 |
AU4560801A (en) | 2001-10-03 |
EP1882690A3 (en) | 2008-04-23 |
IL151474A0 (en) | 2003-04-10 |
EP1265878B1 (en) | 2011-07-13 |
IL151474A (en) | 2009-09-01 |
EP1882690A2 (en) | 2008-01-30 |
TWI310383B (en) | 2009-06-01 |
EP1265878A1 (en) | 2002-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20011104A1 (es) | Un proceso para la preparacion de analogos de epotilona | |
PE20020721A1 (es) | Derivados de quinuclidina como agentes antimuscarinicos m3 | |
PA8591701A1 (es) | Derivados de pirrolopirimidina | |
PE20040570A1 (es) | Tiadiazoldioxidos y tiadiazoloxidos como ligandos del receptor de cxc- y cc-quimiocina | |
JP6043355B2 (ja) | ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 | |
PE20030612A1 (es) | Benzoimidazoles | |
AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
RU2005132930A (ru) | Аналоги простагландина в качестве антагонистов ep4 рецепторов | |
PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
AR043437A1 (es) | Derivados de cianopiridina utiles en el tratamiento de cancer y otros trastornos | |
AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
AR038786A1 (es) | Compuesto de urea, procedimiento para su preparacion, su uso para fabricar un medicamento y composicion farmaceutica que lo comprende | |
PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
MA28012A1 (fr) | Derives de pyridyle et utilisation de ceux-ci en tant qu'agents therapeutiques | |
AR040971A1 (es) | Compuestos pirimido que tienen actividad antiproliferativa | |
RU2003128311A (ru) | Способ лечения резистентных опухолей с применением аналогов эпотилона | |
NZ516821A (en) | Medicaments for treating certain cancers using an estrogen agonist/antagonist | |
MA31894B1 (fr) | Composes organiques | |
AR030211A1 (es) | Compuestos derivados de amino-pirazol, composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por la actividad de la quinasa proteinica | |
AR047557A1 (es) | Compuestos derivados de piridazina y su uso como agentes terapeuticos | |
AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
TW201300384A (zh) | 新穎的雙環吡啶酮類 | |
PE20210154A1 (es) | Derivados de piridincarbonilo y usos terapeuticos de los mismos como inhibidores de trpc6 | |
PE20020468A1 (es) | Compuestos macrolidos como agentes antibacterianos y antiprotozoarios |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |